IMDX PE Ratio & Valuation, Is IMDX Overvalued

Historical Valuation

Insight Molecular Diagnostics Inc (IMDX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 14.80 is considered Undervalued compared with the five-year average of -4.98. The fair price of Insight Molecular Diagnostics Inc (IMDX) is between 5.17 to 14.15 according to relative valuation method. Compared to the current price of 3.76 USD , Insight Molecular Diagnostics Inc By Undervalued By 27.33%.

Relative Value

Fair Zone

5.17-14.15

Current Price：3.76

27.33%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Insight Molecular Diagnostics Inc (IMDX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Insight Molecular Diagnostics Inc (IMDX) has a current Price-to-Book (P/B) ratio of -3.84. Compared to its 3-year average P/B ratio of 14.00, the current P/B ratio is approximately -127.45% higher. Relative to its 5-year average P/B ratio of 14.00, the current P/B ratio is about -127.45% higher. Insight Molecular Diagnostics Inc (IMDX) has a Forward Free Cash Flow (FCF) yield of approximately -20.97%. Compared to its 3-year average FCF yield of -20.43%, the current FCF yield is approximately 2.69% lower. Relative to its 5-year average FCF yield of -20.43%, the current FCF yield is about 2.69% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for IMDX competitors is 7.10, providing a benchmark for relative valuation. Insight Molecular Diagnostics Inc Corp (IMDX.O) exhibits a P/S ratio of 13.54, which is 90.72% above the industry average. Given its robust revenue growth of -23.35%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of IMDX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of IMDX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is IMDX currently overvalued or undervalued?

Insight Molecular Diagnostics Inc (IMDX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 14.80 is considered Undervalued compared with the five-year average of -4.98. The fair price of Insight Molecular Diagnostics Inc (IMDX) is between 5.17 to 14.15 according to relative valuation method. Compared to the current price of 3.76 USD, Insight Molecular Diagnostics Inc is Undervalued By 27.33%.

What is Insight Molecular Diagnostics Inc (IMDX) fair value?

IMDX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Insight Molecular Diagnostics Inc (IMDX) is between 5.17 to 14.15 according to relative valuation method.

How does IMDX's valuation metrics compare to the industry average?

The average P/S ratio for IMDX's competitors is 7.10, providing a benchmark for relative valuation. Insight Molecular Diagnostics Inc Corp (IMDX) exhibits a P/S ratio of 13.54, which is 90.72% above the industry average. Given its robust revenue growth of -23.35%, this premium appears unsustainable.

What is the current P/B ratio for Insight Molecular Diagnostics Inc (IMDX) as of Apr 05 2026?

As of Apr 05 2026, Insight Molecular Diagnostics Inc (IMDX) has a P/B ratio of -3.84. This indicates that the market values IMDX at -3.84 times its book value.

What is the current FCF Yield for Insight Molecular Diagnostics Inc (IMDX) as of Apr 05 2026?

As of Apr 05 2026, Insight Molecular Diagnostics Inc (IMDX) has a FCF Yield of -20.97%. This means that for every dollar of Insight Molecular Diagnostics Inc's market capitalization, the company generates -20.97 cents in free cash flow.

What is the current Forward P/E ratio for Insight Molecular Diagnostics Inc (IMDX) as of Apr 05 2026?

As of Apr 05 2026, Insight Molecular Diagnostics Inc (IMDX) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Insight Molecular Diagnostics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Insight Molecular Diagnostics Inc (IMDX) as of Apr 05 2026?

As of Apr 05 2026, Insight Molecular Diagnostics Inc (IMDX) has a Forward P/S ratio of 14.80. This means the market is valuing IMDX at $14.80 for every dollar of expected revenue over the next 12 months.

IMDX Valuation